Haleon cut its 2026 organic revenue growth target to about 2.5% from 3-5%, citing softer cough/cold demand and weaker North America restocking. Q3 organic growth was 2.6%, with Oral Health growth strong but overall softness. A regulatory halt on Centrum in China and a faster Brazil go-to-market rollout will weigh near-term revenue, contributing to the stock’s slide to a new 52-week low.
Haleon, the maker of Sensodyne, disclosed a memo with CEO Brian McNamara warning of difficult choices ahead. The Reuters-sourced memo offers no concrete numbers or guidance, signaling near-term uncertainty despite stable toothpaste demand. The development could imply strategic or cost actions, potentially impacting margins and growth and HLN's near-term performance.
HLN said U.S. sales of its side-effect countermeasures are rising, riding the GLP-1 wave. This expands HLN's exposure to the booming weight-loss drug ecosystem and broader consumer-health portfolio. If demand persists, HLN could see revenue lift and stronger positioning in a high-growth category, potentially supporting multiple expansion and profitability metrics.
Haleon announced a five-year collaboration with Microsoft to scale digital, data and AI capabilities across its global operations, expanding the use of Azure, Copilot and agentic AI. The partnership aims to accelerate Haleon's Win as One strategy by improving consumer insights, R&D, supply chain and marketing, enabling faster decision-making and potentially reaching one billion more consumers by 2030.
Haleon is intensifying its expansion efforts in China, focusing on second- and third-tier cities while customizing its gum-health products to meet local preferences. This strategy aims to achieve success where many Western brands have previously struggled, potentially leading to significant revenue growth and enhanced market positioning.
Haleon has reported a slowdown in fourth-quarter revenue growth, primarily due to a delayed flu season affecting sales of its respiratory health products. This trend could raise concerns among investors about seasonal performance and future sales forecasts.